Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now
Evrysdi Growing Fast
Executive Summary
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.
You may also be interested in...
Flat Is The New Up As Biogen Anticipates Stabilizing Product Revenue In 2024
With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.
SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.